BCLI — Brainstorm Cell Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Brainstorm Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.5 | -24.3 | -17.2 | -11.6 | -10.3 |
| Depreciation | |||||
| Non-Cash Items | 1.37 | 1.68 | -3.04 | 0.603 | 1.34 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.43 | 2.99 | -0.496 | 1.69 | 1.79 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -26.3 | -19.3 | -20.5 | -9.09 | -6.97 |
| Capital Expenditures | -0.33 | -0.029 | -0.018 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.653 | 1.03 | 2.21 | 0.012 | — |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | 0.323 | 0.998 | 2.19 | 0.012 | — |
| Financing Cash Flow Items | — | — | — | — | 0.45 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.97 | 0.238 | 19 | 7.97 | 6.88 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -19 | -18.1 | 0.713 | -1.11 | -0.095 |